Acadia Pharmaceuticals (ACAD) Stock: Here’s What You Need To Know!

Acadia Pharmaceuticals (NASDAQ:ACAD) On Monday, Acadia Pharmaceuticals announced that it had initiated a phase 2 trial in patients with Alzheimer’s Disease Agitation. Once again ACAD will use its drug Pimavanserin to see if the drug will work in this targeted indication. The company has already received FDA approval for Pimavanserin in Parkinson’s Disease Psychosis. Now … Read more

Biotech Stock News (RXII) (GNCA)

Rxi Pharmaceuticals (NASDAQ:RXII) On Thursday March 31, 2016 Rxi Pharmaceuticals announced that it had received a patent from the United States Patent and Trademark Office — USPTO — for the company’s sd-rxRNA technology platform that covers CTGF — Connective Tissue Growth Factor. In essence the patent covers the company’s lead clinical product RXI-109, which is … Read more

Biotech Stock News (AMGN) (RGLS) (BIIB) (RVNC) (AGN)

Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more

Biotech Stock News (BLUE) (SNTA) (MACK) (BXLT)

Bluebird Bio (NASDAQ:BLUE)¬† On October 19, 2015 shares of Bluebird Bio fell approximately 4% after the company announced that one patient on its old generation gene therapy had required two blood transfusions due to anemia. One thing to keep in mind was that this patient was blood transfusion free for 7 years and that’s why … Read more

Biotech Stock News: (GALE) (AMGN) (ARIA) (BXLT)

Galena Biopharma (NASDAQ:GALE) On Monday August 24, 2015 Shares of Galena Biopharma were able to close the day up 11% after announcing an update for its phase 3 trial known as the “PRESENT” trial. The company announced that the independent data monitoring committee — IDMC — concluded that it would be able to reduce the … Read more

Biotech Stock News (SRPT) (JUNO) (CELG) (AGTC) (VRTX)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 29, 2015 Sarepta had announced that it had completed¬†its rolling submission of its New Drug Application — NDA — to the FDA. A rolling submission is an FDA policy whereby biotech companies can submit their marketing approval application in small parts on a rolling basis instead of doing it … Read more